If you would like to submit a blog post for consideration, please email email@example.com
Consensus on the Practical Use of Botulinum Toxin A
Consensus has been sought on the practical use of Botulinum toxin A (botox) as it becomes a more and more popular cosmetic procedure.
In 2015, botulinum toxin type A (BTX-A) was the most frequently delivered minimally-invasive cosmetic procedure, with over 6.7 million mediated aesthetic interventions performed. The United States Food and Drug Administration (FDA) approved BTX-A in aesthetic medical use for the treatment of glabella lines and lateral canthal rhytides. It is also approved in Australia and New Zealand as a neuromodulator for the treatment of crow’s feet, glabellar and forehead lines.
BTX-A formulations commonly used for such procedures include abobotulinum toxin A, incobotulinumtoxinA, and onabotulinumtoxinA. However, each neurotoxin formulation is different due to varying manufacturing processes. These unique properties and characteristics mean that different neurotoxins must not be used in an interchangeable manner. Importantly, incobotulinumtoxinA contains the same neurotoxin compound as other commercial BTX-A products; however, unlike those other products, it is purified during manufacturing to remove non-active complexing proteins, which have not been proven to be either functional or necessary.
Click here to access the full paper
Source: PRIME International Journal of Aesthetic and Anti-Ageing Medicine
Authors: Niamh Corduff, Michael Kane, Mary Dingley, Joanna Romanowska, Adam Rish, and Ronald Feiner
One comment on “Consensus on the Practical Use of Botulinum Toxin A”